Pharmaceutical Preparations
Mirum Pharmaceuticals, Inc. (MIRM) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 49/100 — a percentile rank of Mirum Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers.
Is Mirum Pharmaceuticals, Inc. overvalued? P/S looks fair vs its 5-year range.
Consensus: Buy from 18 analysts (Strong buy 1 · Buy 17).
Average price target: $155.80 (+62.3% vs $96.00); range $130–$202.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 1 · Open-market sells: 23 · Net: −$9.1M
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!